Using nanobodies to fight drug-resistant bacterial infections
Investigating nanobodies to target multidrug resistant bacterial pathogens
This study is working on a new treatment for tough bacterial infections that don't respond to regular antibiotics, using a special combination of tiny antibodies and bacteria-fighting proteins to help people, especially those with weaker immune systems, get better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-10661648 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of treatment for bacterial infections that are resistant to multiple drugs. It combines the effectiveness of antimicrobial peptides, which can kill bacteria, with the beneficial properties of antibodies, which help the immune system. By using a special type of antibody called a nanobody, the researchers aim to create a powerful new antimicrobial agent that can be used safely in patients, especially those with weakened immune systems. The project employs advanced techniques to identify and optimize these nanobodies for better performance against resistant bacteria.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by multidrug-resistant bacteria, particularly those with compromised immune systems.
Not a fit: Patients with infections caused by non-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively combat multidrug-resistant bacterial infections, improving patient outcomes.
How similar studies have performed: Other research has shown promise in using nanobodies and antimicrobial peptides, suggesting that this approach could be effective.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Davies, Bryan William — University of Texas at Austin
- Study coordinator: Davies, Bryan William
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.